Compare American Tower Corp (AMT) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs Illumina, Inc. — how do they compare? American Tower Corp trades at $169.49 (market cap $79.00B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: American Tower Corp is far larger — about 2.7× Illumina, Inc.'s market cap, and American Tower Corp pays a 4.12% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| AMT | ILMN | |
|---|---|---|
Market Cap | $79.00B | $29.12B |
Sector | Real Estate | Health |
52-Week High | $211.88 | $205.10 |
52-Week Low | $162.11 | $91.00 |
Enterprise Value | $122.53B | $30.48B |
Dividend Yield | 4.12% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
